308 related articles for article (PubMed ID: 27668537)
1. A recombinant protein TmSm(T34A) can inhibit proliferation and proapoptosis to breast cancer stem cells(BCSCs) by down-regulating the expression of Cyclin D1.
Ma X; Zhang Y; Kang Y; Li L; Zheng W
Biomed Pharmacother; 2016 Dec; 84():373-381. PubMed ID: 27668537
[TBL] [Abstract][Full Text] [Related]
2. Salinomycin possesses anti-tumor activity and inhibits breast cancer stem-like cells via an apoptosis-independent pathway.
An H; Kim JY; Lee N; Cho Y; Oh E; Seo JH
Biochem Biophys Res Commun; 2015 Oct; 466(4):696-703. PubMed ID: 26407842
[TBL] [Abstract][Full Text] [Related]
3. Preliminary study of the effects of β-elemene on MCF-7/ADM breast cancer stem cells.
Dong Y; Li L; Wang L; Zhou T; Liu JW; Gao YJ
Genet Mol Res; 2015 Mar; 14(1):2347-55. PubMed ID: 25867381
[TBL] [Abstract][Full Text] [Related]
4. Ultrasound reverses chemoresistance in breast cancer stem cell like cells by altering ABCG2 expression.
Guo L; Zheng P; Fan H; Wang H; Xu W; Zhou W
Biosci Rep; 2017 Dec; 37(6):. PubMed ID: 28935760
[TBL] [Abstract][Full Text] [Related]
5. Genetic protein TmSm(T34A) enhances sensitivity of chemotherapy to breast cancer cell lines as a synergistic drug to doxorubicin.
Xu Y; Zheng W; Wang T; Wang P; Zhu L; Ma X
Biomed Pharmacother; 2012 Jul; 66(5):368-72. PubMed ID: 22560635
[TBL] [Abstract][Full Text] [Related]
6. GSKJ4, an H3K27me3 demethylase inhibitor, effectively suppresses the breast cancer stem cells.
Yan N; Xu L; Wu X; Zhang L; Fei X; Cao Y; Zhang F
Exp Cell Res; 2017 Oct; 359(2):405-414. PubMed ID: 28823831
[TBL] [Abstract][Full Text] [Related]
7. The Hedgehog signalling pathway mediates drug response of MCF-7 mammosphere cells in breast cancer patients.
He M; Fu Y; Yan Y; Xiao Q; Wu H; Yao W; Zhao H; Zhao L; Jiang Q; Yu Z; Jin F; Mi X; Wang E; Cui Z; Fu L; Chen J; Wei M
Clin Sci (Lond); 2015 Nov; 129(9):809-22. PubMed ID: 26201092
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of CXCR7 inhibits proliferative capacity and stem cell-like properties in breast cancer stem cells.
Tang X; Li X; Li Z; Liu Y; Yao L; Song S; Yang H; Li C
Tumour Biol; 2016 Oct; 37(10):13425-13433. PubMed ID: 27460092
[TBL] [Abstract][Full Text] [Related]
9. miR-221/222 enhance the tumorigenicity of human breast cancer stem cells via modulation of PTEN/Akt pathway.
Li B; Lu Y; Wang H; Han X; Mao J; Li J; Yu L; Wang B; Fan S; Yu X; Song B
Biomed Pharmacother; 2016 Apr; 79():93-101. PubMed ID: 27044817
[TBL] [Abstract][Full Text] [Related]
10. microRNA-128-3p overexpression inhibits breast cancer stem cell characteristics through suppression of Wnt signalling pathway by down-regulating NEK2.
Chen Y; Wu N; Liu L; Dong H; Liu X
J Cell Mol Med; 2020 Jul; 24(13):7353-7369. PubMed ID: 32558224
[TBL] [Abstract][Full Text] [Related]
11. Targeting cancer stem cells in breast cancer: potential anticancer properties of 6-shogaol and pterostilbene.
Wu CH; Hong BH; Ho CT; Yen GC
J Agric Food Chem; 2015 Mar; 63(9):2432-41. PubMed ID: 25686711
[TBL] [Abstract][Full Text] [Related]
12. Enhanced SLC34A2 in breast cancer stem cell-like cells induces chemotherapeutic resistance to doxorubicin via SLC34A2-Bmi1-ABCC5 signaling.
Ge G; Zhou C; Ren Y; Tang X; Wang K; Zhang W; Niu L; Zhou Y; Yan Y; He J
Tumour Biol; 2016 Apr; 37(4):5049-62. PubMed ID: 26546432
[TBL] [Abstract][Full Text] [Related]
13. Targeting breast cancer stem cells by a self-assembled, aptamer-conjugated DNA nanotrain with preloading doxorubicin.
Xu Z; Ni R; Chen Y
Int J Nanomedicine; 2019; 14():6831-6842. PubMed ID: 31695364
[TBL] [Abstract][Full Text] [Related]
14. MicroR-760 suppresses cancer stem cell subpopulation and breast cancer cell proliferation and metastasis: By down-regulating NANOG.
Han ML; Wang F; Gu YT; Pei XH; Ge X; Guo GC; Li L; Duan X; Zhu MZ; Wang YM
Biomed Pharmacother; 2016 May; 80():304-310. PubMed ID: 27133070
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D compounds reduce mammosphere formation and decrease expression of putative stem cell markers in breast cancer.
Wahler J; So JY; Cheng LC; Maehr H; Uskokovic M; Suh N
J Steroid Biochem Mol Biol; 2015 Apr; 148():148-55. PubMed ID: 25445919
[TBL] [Abstract][Full Text] [Related]
16. Diallyl Disulfide Inhibits Breast Cancer Stem Cell Progression and Glucose Metabolism by Targeting CD44/PKM2/AMPK Signaling.
Xie X; Huang X; Tang H; Ye F; Yang L; Guo X; Tian Z; Xie X; Peng C; Xie X
Curr Cancer Drug Targets; 2018; 18(6):592-599. PubMed ID: 29110616
[TBL] [Abstract][Full Text] [Related]
17. Mithramycin A sensitizes therapy-resistant breast cancer stem cells toward genotoxic drug doxorubicin.
Saha S; Mukherjee S; Mazumdar M; Manna A; Khan P; Adhikary A; Kajal K; Jana D; Sa G; Mukherjee S; Sarkar DK; Das T
Transl Res; 2015 May; 165(5):558-77. PubMed ID: 25468484
[TBL] [Abstract][Full Text] [Related]
18. Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy.
Pham PV; Phan NL; Nguyen NT; Truong NH; Duong TT; Le DV; Truong KD; Phan NK
J Transl Med; 2011 Dec; 9():209. PubMed ID: 22152097
[TBL] [Abstract][Full Text] [Related]
19. Lentivirus-mediated shRNA targeting Nanog inhibits cell proliferation and attenuates cancer stem cell activities in breast cancer.
Hu C; Xu L; Liang S; Zhang Z; Zhang Y; Zhang F
J Drug Target; 2016; 24(5):422-32. PubMed ID: 26339994
[TBL] [Abstract][Full Text] [Related]
20. miR-638 represses the stem cell characteristics of breast cancer cells by targeting E2F2.
Lin QY; Wang JQ; Wu LL; Zheng WE; Chen PR
Breast Cancer; 2020 Jan; 27(1):147-158. PubMed ID: 31410735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
